Role of bone marrow-derived mesenchymal stem cells in a rat model of severe acute pancreatitis

Table 1 Measurement of cell survival rate by the 3-(4,5-dimethylthiazol-2-yl)-2-,5-diphenyltetrazolium bromide assay of pancreatic acinar cells at various time points (mean ± SD)

Group	0.5 h	1 h	4 h	10 h
Non-SODC group	93.83% ± 3.13%	89.00% ± 2.83%	81.83% ± 3.06%	75.00% ± 6.54%
SODC group	87.83% ± 6.59%a	77.50% ± 9.35%a	65.83% ± 8.23%a	39.17% ± 8.26%a
MSCs intervention group	90.00% ± 3.41%	82.17% ± 7.47%	75.17% ± 5.85%c	51.83% ± 6.79%c

^aP < 0.05 vs the non-sodium deoxycholate (SDOC) group,

^cP < 0.05 vs the SDOC group. MSCs: Mesenchymal stem cells.

Table 2 Changes in amylase secretion rate and lactate dehydrogenase leakage rate of pancreatic acinar cells at various time points (mean ± SD)

Index	Group	0.5 h	1 h	4 h	10 h
AMS	Non-SDOC group	7.47 ± 0.67	8.97 ± 0.69	20.32 ± 2.00	24.28 ± 2.47
	SDOC group	11.75 ± 2.40a	17.23 ± 2.43a	40.88 ± 3.61a	60.38 ± 4.01a
	MSCs intervention group	10.18 ± 1.53	14.48 ± 1.74c	29.33 ± 2.16c	40.33 ± 4.27c
LDH	Non-SDOC group	3.00 ± 0.63	3.47 ± 0.59	13.17 ± 2.86	23.40 ± 2.55
	SDOC group	7.65 ± 1.75a	12.00 ± 3.17a	39.02 ± 2.38a	53.70 ± 6.73a
	MSCs intervention group	5.35 ± 1.01c	8.33 ± 3.08c	27.67 ± 3.39c	38.33 ± 3.20c

^aP < 0.05 vs the non-sodium deoxycholate (SDOC) group;

^cP < 0.05 vs the SDOC group. MSCs: Mesenchymal stem cells; AMS:Amylase; LDH: Lactate dehydrogenase.

Table 3 Comparison of superoxide dismutase and malonaldehyde levels in pancreatic acinar cell culture supernatants at various time points (mean ± SD)

Index	Group	0.5 h	1 h	4 h	10 h
Superoxide dismutase (U/mL)	Non-SDOC group	194.83 ± 26.48	185.83 ± 37.79	170.00 ± 25.42	165.00 ± 31.72
	SDOC group	116.17 ± 28.85a	108.00 ± 41.52a	102.00 ± 33.45a	90.67 ± 33.55a
	MSCs intervention group	125.50 ± 39.20	138.50 ± 42.03	147.67 ± 37.25c	139.00 ± 46.22c
Malonaldehyde (μmol/L)	Non-SDOC group	3.50 ± 5.84	4.17 ± 0.75	4.33 ± 1.27	4.67 ± 1.21
	SDOC group	4.40 ± 1.33	6.33 ± 1.63a	7.33 ± 1.21a	8.00 ± 1.10a
	MSCs intervention group	3.97 ± 0.89	5.00 ± 1.41	5.33 ± 1.63c	5.83 ± 2.04c

^aP < 0.05 vs the non-sodium deoxycholate (SDOC) group;

^cP < 0.05 vs the SDOC group.

Table 4 Comparisons of serum amylase levels (U/L) in rats that were or were not treated with mesenchymal stem cells following establishment of an severe acute pancreatitis model (n = 36, mean ± SD)

Group	Post-MSCs or saline injection (h)
	6	24	72
SAP	3753.83 ± 791.65	5344.67 ± 649.63	7762.50 ± 977.30
SAP + MSCs	2671.33 ± 547.57a	4235.83 ± 554.57a	5615.17 ± 809.30b

^aP < 0.05,

^bP < 0.01 vs the severe acute pancreatitis (SAP) group. MSCs: Mesenchymal stem cells.

Table 5 Comparison of serum malonaldehyde, superoxide dismutase levels, interleukin-6, interleukin-10 and tumor necrosis factor-α measured at various time points after injecting either mesenchymal stem cells or saline into rats after establishing an severe acute pancreatitis model (n = 36, mean ± SD)

Index	Group	Post-mesenchymal stem cells or saline injection (h)
		6	24	72
Malonaldehyde (nmol/mL)	Severe acute pancreatitis group	4.89 ± 0.97	5.20 ± 1.21	4.43 ± 0.42
	Severe acute pancreatitis + mesenchymal stem cells group	3.68 ± 0.38a	3.89 ± 0.59a	3.36 ± 0.98a
Superoxide dismutase (U/mL)	Severe acute pancreatitis group	43.16 ± 6.94	48.13 ± 3.93	45.83 ± 4.72
	Severe acute pancreatitis + mesenchymal stem cells group	48.05 ± 3.83	61.29 ± 7.81b	50.75 ± 7.59
Interleukin-6 (pg/mL)	Severe acute pancreatitis group	107.70 ± 13.08	128.52 ± 8.52	134.06 ± 13.12
	Severe acute pancreatitis + mesenchymal stem cells group	90.16 ± 9.55a	107.33 ± 12.13b	143.24 ± 12.11
Interleukin-10 (pg/mL)	Severe acute pancreatitis group	31.08 ± 6.64	45.02 ± 4.28	40.11 ± 8.39
	Severe acute pancreatitis + mesenchymal stem cells group	40.84 ± 7.05a	52.08 ± 5.79a	41.76 ± 3.37
TNF-α (pg/mL)	Severe acute pancreatitis group	106.15 ± 9.01	132.62 ± 8.64	122.42 ± 13.44
	Severe acute pancreatitis + mesenchymal stem cells group	91.47 ± 10.00a	119.47 ± 10.83a	110.91 ± 9.92

^aP < 0.05,

^bP < 0.01 vs the severe acute pancreatitis group. TNF-α: Tumor necrosis factor-α.

Table 6 Comparison of intestinal mucosa injury scores (each slice/score) and proliferating cells of small intestinal mucosa (each slice/number) determined at various time points after injecting either mesenchymal stem cells or saline after establishment of an severe acute pancreatitis model (n = 36, mean ± SD)

Group	Post-MSCs or saline injection (h)
	6		24		72
	Intestinal mucosa injury scores	proliferating cells number	Intestinal mucosa injury scores	proliferating cells number	Intestinal mucosa injury scores	proliferating cells number
SAP group	43.33 ± 4.84	39.50 ± 5.09	52.83 ± 5.27	59.67 ± 6.80	32.17 ± 4.17	81.50 ± 7.89
SAP + MSCs group	36.33 ± 5.72a	40.83 ± 5.12	46.33 ± 2.80a	68.00 ± 3.22a	26.67 ± 3.08a	101.00 ± 11.58b

^aP < 0.05,

^bP < 0.01 vs the severe acute pancreatitis (SAP) group. MSCs: Mesenchymal stem cells.